FDA Fails to Provide Credible Data on Kratom

FDA Fails to Provide Credible Data and Science to Justify Scheduling Kratom as Schedule I Substance

The U.S. Food and Drug Administration’s efforts to have kratom listed as a Schedule I substance under the Controlled Substances Act (CSA) is filled with errors and omissions, according to a new report from the American Kratom Association (AKA).  The AKA report maintains that FDA fails to meet the burden of proof necessary to propose such a radical change in Kratom’s regulatory status.

“To meet the standard, which would put kratom on par with heroin, LSD, Quaaludes, and peyote, the FDA must submit an eight-factor analysis that conclusively demonstrates with scientific evidence that kratom is dangerously addictive and presents a risk to the safety of the public,” explains Charles M. “Mac” Haddow, Senior Fellow of Public Policy at the American Kratom Association.  “They have clearly failed to meet that prerequisite.”

READ FULL STORY

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *